Key Takeaway: Vir Biotechnology, Inc. has announced its participation in several investor conferences scheduled for March 2026. The management team will engage in live webcasts, which will be available for 30 days post-event. The company focuses on developing treatments for infectious diseases and cancer, showcasing its commitment to innovation in biopharmaceuticals.
Price reaction · baseline $9.32 (2026-02-26 close) · hit pre-market · clean, no other VIR news in the window
day 0 close · peak
-2.5%
Market Sentiment Analysis
POSITIVE FACTORS
Vir Biotechnology is actively engaging with investors through conferences.
The company has a diverse clinical-stage portfolio targeting serious diseases.
Live webcasts will enhance accessibility for investors.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
14%
average across 4 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis
Full Press Release Details
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March:
Live webcasts of the fireside chats will be available athttps://investors.vir.bioand will be archived for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN®dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology has exclusive rights to the universal PRO-XTEN®masking platform for oncology and infectious disease. PRO-XTEN®is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Frequently Asked Questions
When will Vir Biotechnology participate in investor conferences?
Vir Biotechnology will participate in investor conferences during March 2026.
How can investors access the conference webcasts?
Investors can access the live webcasts on Vir's investor website, archived for 30 days.
What is the focus of Vir Biotechnology's portfolio?
Vir Biotechnology focuses on developing treatments for serious infectious diseases and cancer.
What is the PRO-XTEN platform?
The PRO-XTEN platform is a universal masking technology for oncology and infectious diseases.